BILLERICA, Mass., Feb 25, 2010 (BUSINESS WIRE) -- Bruker Corporation (NASDAQ: BRKR) today reported financial results for
the fourth quarter and year ended December 31, 2009.

Financial Results

In the fourth quarter of 2009, GAAP revenue increased by 16% to $366.4
million, compared to revenue of $315.2 million in the fourth quarter of
2008. Excluding the effects of foreign currency translation, fourth
quarter revenue increased by 6% year-over-year. In the fourth quarter of
2009, GAAP revenue increased by 13% year-over-year for the Bruker
Scientific Instruments (BSI) segment, and by 116% year-over-year for the
Bruker Energy & Supercon Technologies (BEST) segment.

GAAP operating income in the fourth quarter of 2009 was $76.2 million,
compared to $48.9 million in the fourth quarter of 2008. GAAP net income
for the fourth quarter of 2009 was $43.5 million, or $0.26 per diluted
share, compared to $26.2 million, or $0.16 per diluted share, in the
fourth quarter of 2008. Included in GAAP EPS for the fourth quarter 2009
was non-cash stock-based compensation expense of ($0.01) per diluted
share, the same as in the fourth quarter of 2008.

For the year 2009, GAAP revenue increased by 1% to $1,114.5 million,
compared to revenue of $1,107.1 million for the year 2008. Excluding the
effects of foreign currency translation, full year 2009 revenue
increased by 2% year-over-year. For the year 2009, GAAP revenue
decreased 1% to $1,062.7 million for the BSI segment, and increased 37%
to $59.8 million for the BEST segment, compared to the year 2008.

For the year 2009, GAAP operating income was $136.7 million, compared to
$108.2 million for the year 2008. Operating income for the BSI segment
in 2009 was $141.7 million, compared to $116.2 million in 2008. In the
year 2009, BSI operating income was favorably impacted by $6.7 million,
or by 60 basis points, upon recognizing revenue for the world's first 1
GHz NMR system, for which the majority of R&D expenses were recorded
prior to 2009.

For the year 2009, GAAP net income was $81.2 million, or $0.49 per
diluted share, compared to $64.9 million, or $0.39 per diluted share, in
2008. Included in GAAP EPS for the full year 2009 was non-cash
stock-based compensation expense of ($0.03) per diluted share, compared
to ($0.02) per diluted share for 2008. For the year 2009, the BSI
segment contributed GAAP earnings of $0.53 per diluted share, compared
to $0.44 in 2008. For the year 2009, the BEST segment contributed a GAAP
loss of ($0.04) per diluted share, compared to ($0.05) in 2008.

Cash flow from operations for the full year 2009 was $149.8 million,
compared to $106.9 million in 2008. Free cash flow, defined as operating
cash flow less capital expenditures, was $131.7 million during 2009,
compared to $59.5 million during 2008. During the year 2009, the Company
repaid $86.1 million of debt, and as of December 31, 2009, Bruker had
cash, cash equivalents and restricted cash of $209.1 million and net
cash of $71.4 million.

Comment and Outlook

Frank Laukien, President and CEO, commented: "Given the challenging
economic conditions in 2009, we are extremely pleased that we could
exceed our full-year 2009 financial goals with year-over-year

• 
  currency-adjusted total revenue growth of 2%,
  


• 
  BSI improvement in GAAP operating margin of 250 basis points,
  



• 
  BSI increase in GAAP net income of 19%, plus excellent improvements in
  cash flow.
  

This success is directly attributable to the strength of our
high-performance, innovative scientific instruments and analytical
solutions portfolio, as well as to the enthusiasm and customer focus of
our global Bruker team.

Moreover, we are also pleased with the recent acceleration in growth of
BEST, which more than doubled its fourth quarter 2009 revenue
year-over-year. We are optimistic about the prospects for this
'intrapreneurial' venture, as BEST further develops its broad technology
base in superconducting materials and devices, in order to address
potentially large emerging markets in clean tech, alternative energy and
'big science' infrastructure."

Dr. Laukien continued: "In 2010, as Bruker celebrates its 50^th
anniversary, our goal is to build on our success over the past 50 years
by remaining true to our innovation and profitable growth strategy. We
believe that our commitment to R&D and customer focus, coupled with
emphasis on operational excellence, can generate further improvements in
financial performance. Our financial goals for the year 2010 are:

• 
  total Bruker currency-adjusted revenue growth of greater than 5%,
  


• 
  BSI operating margin improvement of greater than 125 basis points,
  excluding the 60 basis point favorable impact from the 1 GHz NMR
  recognized in 2009,
  


• 
  BSI net income and EPS increase of greater than 15%, and
  



• 
  BSI working capital decrease of more than 5%.
  

For our BEST segment, in 2010 we plan greater than 25% revenue growth,
continued infrastructure, marketing and R&D investments for clean-tech
and alternative energy applications, with an expected BEST 2010
operating loss of $7-8 million."

EARNINGS CONFERENCE CALL

Bruker Corporation will host an operator-assisted earnings conference
call at 9:00 a.m. Eastern Time on Thursday, February 25, 2010. To listen
to the webcast, investors can go to http://ir.bruker.com
and click on the live web broadcast symbol. The webcast will be
available through the Company web site for 30 days. Investors can also
listen and participate on the telephone in the US and Canada by calling
800-688-0796, or +1-617-614-4070 outside the US and Canada. Investors
should refer to the Bruker Earnings Call. A telephone replay of the
conference call will be available one hour after the conference call by
dialing 888-286-8010 in the US and Canada, or +1-617-801-6888 outside
the US and Canada, and then entering replay pass code 24438469. For more
information, please visit http://ir.bruker.com

CAUTIONARY STATEMENT

Any statements contained in this presentation that do not describe
historical facts may constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those projected,
including, but not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility in
the capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product development
and market acceptance of our products, the cost and pricing of our
products, manufacturing, competition, dependence on collaborative
partners and key suppliers, capital spending and government funding
policies, changes in governmental regulations, realization of
anticipated benefits from economic stimulus programs, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in our
filings with the Securities and Exchange Commission. These and other
factors are identified and described in more detail in our filings with
the SEC, including, without limitation, our recent Proxy Statements on
Schedule 14A, our annual report on Form 10-K for the year ended December
31, 2008, our most recent quarterly reports on Form 10-Q and our current
reports on Form 8-K. We expressly disclaim any intent or obligation to
update these forward-looking statements other than as required by law.

SOURCE: Bruker Corporation

Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com